Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Stomach Cancer Market Expected To Reach $7.14 Billion By 2030 At 13.8% CAGR

The global stomach cancer market experienced substantial expansion, projected to increase from $3.74 billion in 2025 to $4.26 billion by 2026, reflecting a compound annual growth rate of 13.9%. This historical market growth was fueled by several key factors, including the escalating global rates of gastric cancer diagnosis, the widespread presence of helicobacter pylori infections, a greater reliance on chemotherapy as a primary treatment modality, the ongoing development of hospital-based cancer treatment facilities, and advancements in medical imaging technologies for disease detection.

The global market for stomach cancer therapies is poised for substantial expansion, projected to reach $7.14 billion by the year 2030, reflecting a compound annual growth rate of 13.8%. This upward trajectory is anticipated to be driven by several key factors: the increasing implementation of precision oncology strategies, amplified investments in the development of innovative biologic treatments, an expanding array of immunotherapy options in clinical development, a heightened emphasis on the early identification of cancerous conditions, and improved accessibility to cutting-edge cancer care modalities. Key developments anticipated within this timeframe include a greater embrace of targeted therapy regimens, a surge in the utilization of combined immunotherapy approaches, a more pronounced focus on early diagnostic screening processes, the broadening application of personalized treatment plans, and a more seamless integration of diagnostic testing guided by biomarkers.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25913&type=smp

Stomach Cancer Market Growth Factors Supporting Long-Term Expansion

The increasing incidence of Helicobacter pylori infections is anticipated to be a key catalyst for the expansion of the stomach cancer market. Helicobacter pylori infection, a condition stemming from the presence of the Helicobacter pylori bacterium within the stomach lining, can incite inflammation, ulcers, and elevate the likelihood of developing stomach cancer. Factors such as inadequate sanitation contribute significantly to the heightened prevalence of this infection, enabling its transmission through fecal-oral and oral-oral routes, particularly in densely populated or unsanitary environments. The mechanism through which Helicobacter pylori infection fuels stomach cancer involves sustained inflammation and cellular damage to the stomach’s mucosal lining, ultimately fostering precancerous alterations and the subsequent growth of tumors. Illustratively, data from November 2024, provided by the Government of Canada, indicated a 19% recurrence rate for Helicobacter pylori infection in 2023, noting that this rate fluctuates depending on geographical region and demographic considerations. Consequently, the escalating occurrence of Helicobacter pylori infections is a primary driver influencing the growth trajectory of the stomach cancer market.

Stomach Cancer Market Segments: Where Are The Largest Growth Opportunities?

The stomach cancer market covered in this report is segmented –

1) By Type: Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor, Other Types

2) By Therapy Type: Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Surgery

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Adenocarcinoma: Intestinal Type, Diffuse Type

2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma, Diffuse Large B-Cell Lymphoma

3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor, Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal, Wild-Type Gastrointestinal Stromal Tumors

4) By Carcinoid Tumor: Typical Carcinoid, Atypical Carcinoid

5) By Other Types: Squamous Cell Carcinoma, Small Cell Carcinoma, Undifferentiated Tumors

Stomach Cancer Market Industry Trends Shaping Future Revenue Growth

In the context of the stomach cancer treatment sector, key players are prioritizing the creation of sophisticated interventions like claudin (CLDN18.2)-targeted cytolytic antibody therapies, aiming to elevate the precision of initial treatments for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinomas. This therapeutic modality utilizes a monoclonal antibody engineered to specifically attach to tumor cells exhibiting CLDN18.2 expression, subsequently triggering cell death when administered concurrently with chemotherapy, thereby improving both progression-free and overall survival rates. Illustrating this trend, Astellas Pharma US, Inc., a pharmaceutical entity headquartered in Japan, introduced Vyloy (zolbetuximab-clzb) in October 2024, a claudin (CLDN18.2)-directed cytolytic antibody formulated for the management of gastric and gastroesophageal junction (GEJ) cancers. This groundbreaking biologic treatment, delivered intravenously in conjunction with chemotherapy regimens containing fluoropyrimidine and platinum, demonstrated a median progression-free survival advantage of up to 10.6 months and an overall survival of up to 18.2 months during clinical investigations. By specifically targeting CLDN18.2-positive malignant cells, this therapy diminishes unintended harm to healthy tissues and enhances therapeutic specificity, representing a substantial stride forward in the field of personalized oncology for advanced stages of gastric cancer.

Stomach Cancer Market Major Participants And Competitive Dynamics

Major companies operating in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc, Daiichi Sankyo Company Limited, BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Zai Lab Limited, MacroGenics Inc., Astellas Pharma Inc., Ipsen Group, AbbVie Inc., Bayer AG, Ono Pharmaceutical Co. Ltd.

Access The Complete Stomach Cancer Market Report:

https://www.thebusinessresearchcompany.com/report/stomach-cancer-global-market-report

Stomach Cancer Market Largest Region: Which Geography Holds The Highest Market Share?

North Americawas the largest region in the stomach cancer market in 2025. Asia-Pacificis expected to be the fastest-growing region in the forecast period. The regions covered in the stomach cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model